

AHCL/SE/49/2019-20

February 12 2020

The National Stock Exchange of India Limited "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E)	BSE Limited Department of Corporate Services 1st Floor, P.J. Towers, Dalal Street,
Mumbai 400 051	Mumbai 400 001
Symbol: AMRUTANJAN	Scrip Code: 590006

Dear Sir / Madam,

Sub: Outcome of the Board Meeting

In terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), we wish to inform that the Board of Directors of the Company at its meeting held today (February 12 2020) had inter-alia:

- (i) Approved the Un-audited Financial Results for the quarter ended December 31 2019. The same along with the Limited Review Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company is enclosed.
- (ii) Declared Second Interim Dividend of Rs. 1.55 per share* for the financial year 2019-20 on the Equity Shares of the Company.

The Board Meeting commenced at 11.00 A.M. and concluded at 14.55 P.M. Request you to take the same on record.

Thanking you,

Yours faithfully,

For Amrutanjan Health Care Limited

(M Srinivasan)

Company Secretary & Compliance Officer

STATUTE CHENNAL A

*(Considering the growth in profits, the Board has increased the 2^{nd} Interim dividend from Re. 0.55 per share (paid in 2018-19) to Rs. 1.55 per share for 2019-20(Special Dividend Re. 1/- per share)

Encl:

- 1. Un-audited Standalone Financials Results for the quarter ended December 31, 2019
- 2. Limited Review Report

Tel :+91-44 - 2499 4465 +91-44 - 2466 9000

Fax:+91-44 - 2499 4585

AMRUTANJAN HEALTH CARE LIMITED

CIN No: L24231TN1936PLC000017

Registered Office: No. 103 (Old No. 42-45), Luz Church Road

Mylapore, Chennai - 600 004

Statement of Unaudited Financial Results for the quarter and nine months ended 31 December 2019

(Rs. in Lakhs) Quarter ended Period ended Year ended **Particulars** 31 December 2018 31 December 2019 31 December 2018 31 March 2019 31 December 2019 30 September 2019 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) (Unaudited) Continuing operations Income from operations 6,993.58 20,215.76 16,808.68 25,322.73 7.480.77 Revenue from operations 8.275.40 159.93 7,153.51 568.04 20,783.80 446.12 17,254.80 713.09 26,035.82 Other income Total income (I + II) 7.667.19 8.501.55 IV Expenses (a) Cost of materials consumed 2,427.56 2,628.77 6,690.48 6,611.78 9,052.32 2.578.88 (b) Purchases of stock-in-trade (c) Changes in inventories of finished goods, work in 894.08 1,103.91 1,001.30 2.827.61 2,146.39 3,164.07 (337.34)(702.51) (67.43)(329.54)140.77 (136.13)progress and stock in trade 2,957.45 2,391.49 831.20 3.336.35 (d) Employee benefits expense 986.69 1.059.94 (e) Advertisement and selling expenditure 1,764.59 1,123.12 1,635.16 3,445.98 3,244.79 4,109.49 (f) Finance cost 4 67 5.03 14.89 5.36 8 22 (g) Depreciation and amortisation expense 122.25 81.40 233.79 315.97 126.66 333.86 749.78 **7,241.71** 2,199.41 18,402.25 1,826.64 15,757.73 2,862.21 22,519.09 (h) Other expenses 744.83 557.17 6,454.92 6,397.66 Total expenses (IV) Profit before tax (III - IV) 1,259.84 1,212.27 755.85 2,381.55 1,497.07 3,516.73 VI Tax expenses 310.56 371.93 203.26 662,41 418.85 1.016.96 VII Profit after tax from continuing operations (V - VI) 949.28 840.34 552 59 1.719.14 1.078.22 2,499.77 Discontinued operations Loss before tax from discontinued operations (23.92)(53.89)(48.34)Tax benefit VIII Loss after tax from discontinued operations (23.92) (53.89) (48.34) IX Profit for the period (VII + VIII) 949.28 840.34 528.67 1,719.14 1,024.33 2,451.43 Other comprehensive income Re-measurement losses / gain on defined benefit plans, net 4.89 (31.48)(20.75)(29.02) (11.12)(56.55)Total other comprehensive income for the period 4.89 (31.48)(20.75)(29.02) (11.12)(56.55)XI Total comprehensive income for the period (IX + X) 954.17 808.86 507.92 1,690.12 1,013.21 2,394.88 Paid-up equity share capital (Face value Re. 1/- each) 292.31 292.31 292.31 292.31 292.31 292.31 Earnings per equity share for continuing operations Basic and diluted earnings per share 3.25 2.87 1.89 5.88 3.69 8.55 (not annualised) (not annualised) (not annualised) (not annualised) (not annualised) (annualised) Earnings per equity share for discontinued operations Basic and diluted earnings per share (0.08) (0.18)(0.17)(not annualised) (not annualised) (not annualised) (not annualised) (annualised) (not annualised) Earnings per equity share for total operations Basic and diluted earnings per share 1.81 3.51 5.88 8.38 (not annualised) (not annualised) (not annualised) (not annualised) (not annualised) (annualised)



See accompanying notes to financial results





AMRUTANJAN HEALTH CARE LIMITED CIN No: L24231TN1936PLC000017 Registered Office: No. 103 (Old No. 42-45), Luz Church Road

Mylapore, Chennai - 600 004

Notes:

& Co.

red Accour

Cha

- 1. The above financial results for the quarter and nine months ended 31 December 2019 in respect of Amrutanjan Health Care Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 12 February 2020. The above results have been subjected to limited review by the statutory auditor of the Company. The auditors have issued an unmodified review report.
- 2. The financial results has been prepared in accordance with recognition and measurement principles laid down in accordance with the Indian Accounting Standard ('Ind AS'), 34 "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations 2015.
- 3. Interim dividend of INR 0.55 per share (55% on par value of INR 1 each), aggregating to INR 193.81 lakhs (including dividend distribution tax) has been paid during the quarter ended 31 December
- 4. The Company has elected to exercise the option permitted under section 115BAA of the Income tax Act, 1961, as introduced by the Taxation laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognised provision for income tax for the quarter and nine month ended 31 December 2019 and re-measured its deferred tax assets/ liabilities in accordance with the said provision.
- 5. Segment reporting in the financial results: Based on the 'management approach' as defined in Ind AS 108 "Operating Segments', the Chief Operating Decision Maker evaluates the Company's performance as OTC Products and Beverages.

Г		Quarter ended			Period ended		Year ended
1	Particulars	31 December 2019	30 September 2019	31 December 2018	31 December 2019	31 December 2018	31 March 2019
L		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Segment revenue	20 13 100 20 100		NOTES CONTROL OF	000000000000000000000000000000000000000	010.00000000000000000000000000000000000	
	OTC Products	8,051.90	7,158.78	6,783.39	18,760.40	15,499.56	23,073.35
	Beverages	165.33	244.82	163.57	1,264.17	1,188.62	2,075.98
C	Others	58.17	77.17	46.62	191.19	120.50	173.40
	Total	8,275.40	7,480.77	6,993.58	20,215.76	16,808.68	25,322.73
2	Segment results						
a	OTC Products	1,176.42	1,206.66	776.80	2,239.55	1,812.78	3,645.74
Ь	Beverages	(66.42)	(90.57)	(93.98)	(148.41)	(499.50)	(367.80)
C	Others	(81.28)	(36.89)	(46.11)	(151.99)	(125.53)	(153.94)
	Total	1,028.72	1,079.20	636.71	1,939.15	1,187.75	3,124.00
ı	Less:				8	51	
1	i) Finance cost	4.67	5.03		14.89	5.36	8.22
1	ii) Other unallocable expenditure net of unallocable income	(235.79)	(138.10)	(119.14)	(457.29)	(314.68)	(400.95)
1	Total profit before tax	1,259.84	1,212.27	755.85	2,381.55	1,497.07	3,516.73
	³						
3	Segment assets					V-1000041100111100111	
a	OTC Products	7,704.92	6,692.00	6,020.90	7,704.92	6,020.90	6,664.80
b	Beverages	1,024.84	999.56	1,062.74	1,024.84	1,062.74	1,071.10
c	Others	49.96	63.06	65.06	49.96	65.06	88.93
d	Unallocated assets	11,792.99	12,151.44	10,507.31	11,792.99	10,507.31	10,936.51
	Total	20,572.71	19,906.06	17,656.01	20,572.71	17,656.01	18,761.34
4	Segment liabilities						
a	OTC Products	4,075.87	3,777.63	3,797.45	4,075.87	3,797.45	3,021.25
b	Beverages	318.12	421.23	214.13	318.12	214.13	644.66
	Others	105.85	50.00	51.97	105.85	51.97	50.00
d	Unallocated liabilities	372.96	717.63	206.69	372.96	206.69	471.80
1 *	Total	4,872.80	4,966.49	4,270.24	4,872.80	4,270.24	4,187.71
L	Total capital employed in the Company	15,699.91	14,939.57	13,385.77	15,699.91	13,385.77	14,573.63

- 6. Effective 1 April 2019, the Company adopted Ind AS 116 "Leases" and applied the standard to lease contracts existing on 1 April 2019 using modified retrospective approach. Accordingly, the comparatives for the year ended 31 March 2019 has not been retrospectively adjusted. On transition, the adoption of new standard resulted in recognition of Right-of-Use (ROU) asset and lease liability.
- 7. During the earlier periods, the Company had decided to discontinue the operations of its Chemical division. Accordingly, the results for the comparative periods in this Statement have been revised to exclude the operations of the Chemical division. The results of the discontinued operations are presented below:

Г			Quarter ended			Period ended	
1	Particulars	31 December 2019	30 September 2019	31 December 2018	31 December 2019	31 December 2018	31 March 2019
L		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total revenue	-	•	2.22	-	20.99	22.87
111	Total expenses		-	26.14	3. 5 3	74.88	71.21
111	Loss before tax (I - II)	-	- 1	(23.92)		(53.89)	(48.34)
IV	Tax benefit		-			-	
V	Loss from discontinued operations (III + IV)			(23.92)		(53.89)	(48.34)

For Amrutanjan Health Care Limited

Date: 12 February 2020 S Sambhu Prasad Place: Chennai

Chairman & Managing Director

BSR&Co.LLP

Chartered Accountants

KRM Tower, 1st & 2nd Floor, No 1, Harrington Road, Chetpet, Chennai - 600 031, India. Telephone : +91 44 4608 3100 Fax : +91 44 4608 3199

Limited Review Report

To Board of Directors of Amrutanjan Health Care Limited

- 1. We have reviewed the accompanying Statement of unaudited standalone financial results of **Amrutanjan Health Care Limited** for the quarter ended and year to date results for the period from 1 April 2019 to 31 December 2019 ("the Statement").
- 2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for BSR & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022

K Raghuram

Partner
Membership No: 211171

UDIN: 20211171AAAAAJ8551

Place: Chennai

Date: 12 February 2020